Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

This study has been completed.
Genentech, Inc.
Information provided by (Responsible Party):
Rush University Medical Center Identifier:
First received: January 9, 2008
Last updated: November 4, 2014
Last verified: November 2014
Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina. The usual treatment is a type of laser, called panretinal photocoagulation. One drawback is that the amount of space within the eye for use of this treatment eventually has its limit, and should not be used too near the part of the retina used for detailed vision (the macula). In similar eye disorders, there are certain injectable medications called anti-VEGF treatments which can slow down or stop this abnormal blood vessel growth. This study sought to compare use of ranibizumab versus standard panretinal photocoagulation in treatment of diabetic neovascularization.

Condition Intervention Phase
Proliferative Diabetic Retinopathy
Drug: ranibizumab
Procedure: Laser photocoagulation
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)

Resource links provided by NLM:

Further study details as provided by Rush University Medical Center:

Primary Outcome Measures:
  • The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) [ Time Frame: Week 4; Month 6 ]
    This is a measurement of how much change in neovascularization has occurred, using the Optomap FA readings to calculate the increase or decrease in surface area of the retina that is affected by neovascularization.

  • The Mean Percentage Change of Macular Edema Measured by Retinal Thickness by OCT (Optical Coherence Tomography) [ Time Frame: Week 4; Month 6 ]
  • Incidence and Severity of Ocular Adverse Events, as Identified by Ophthalmic Examination [ Time Frame: Month 6 ]
  • Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ]

Secondary Outcome Measures:
  • Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters [ Time Frame: Week 4; Month 6 ]
  • Percentage of Patients Gaining 3 or More Lines of Vision According to ETDRS Eye Chart Testing [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ]
  • Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment [ Time Frame: Month 6 ]

Enrollment: 8
Study Start Date: January 2008
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anti-VEGF injection
Intravitreal injection of 0.5-mg dose of ranibizumab
Drug: ranibizumab
One 0.5 mg intravitreal injection
Other Name: Lucentis
Active Comparator: PRP Laser
Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
Procedure: Laser photocoagulation
panretinal photocoagulation (up to 500 300-500 um laser spots)

Detailed Description:
The purpose is to compare the efficacy of ranibizumab versus additional panretinal photocoagulation on diabetic neovascularization that is persistent despite previous treatment with panretinal photocoagulation. We hypothesize that ranibizumab intravitreal injections would induce neovascular regression in similar or better fashion than supplemental laser photocoagulation. Consented, enrolled subjects will either receive open-label intravitreal injections of 0.5-mg dose of ranibizumab or additional panretinal photocoagulation (up to 500 300-500 um laser spots) in a ratio of two-to-one (2:1) at the beginning of the study period. ETDRS best-corrected visual acuity, contrast sensitivity, and Optos color photography will be performed at enrollment, at weeks 1, 2, 3 and 4, and at months 2, 3, 4, 5 and 6. The subjects will undergo fluorescein angiography utilizing the Optomap FA (fluorescein angiography) system and optical coherence tomography (OCT) at enrollment, at weeks 2 and 4, and at months 2, 3, 4 and 6. The subjects will be followed for a 6-month period for stabilization, regression, or recurrence of neovascularization. In addition, patients will be evaluated for occurrence of macular edema.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age 18 years or older

Patient related considerations:

  • Patients with Diabetes Mellitus (Type I or II) are eligible. HgA1c will be evaluated at the beginning of the study, but this value will have no significance in inclusion or exclusion.
  • Patients will not be pregnant at enrollment and must provide evidence of the use of two types of birth control while enrolled in the study.
  • Patients will have no known sensitivity to ranibizumab or other anti-VEGF injections.

Disease related considerations:

  • Patients will have diabetic neovascularization as seen on fluorescein angiography that was previously treated with full (at least 1200 laser burns) panretinal photocoagulation and that has persisted at least three months.
  • There will be no evidence of ocular inflammation at enrollment.
  • There is no restriction on patient's current medications or concomitant illnesses as long as there is no interference with patient follow-up.

Other considerations:

  • Patients may not be enrolled in another clinical study or observational trial.
  • There is no limitation on patient's institutional status as long as the patient is able to participate in follow-up.

Exclusion Criteria:

  • Pregnancy (positive pregnancy test)
  • Uncontrolled glaucoma on three medicines or more to control intraocular pressure
  • Prior enrollment in the study
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00606138

United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Genentech, Inc.
Principal Investigator: Mathew W MacCumber, MD, PhD Rush University Medical Center
  More Information

Responsible Party: Rush University Medical Center Identifier: NCT00606138     History of Changes
Other Study ID Numbers: 06120402
Study First Received: January 9, 2008
Results First Received: December 7, 2012
Last Updated: November 4, 2014

Additional relevant MeSH terms:
Diabetic Retinopathy
Neovascularization, Pathologic
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Pathologic Processes
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on April 21, 2017